FY2027 EPS Estimates for Haemonetics Reduced by Analyst

Haemonetics Co. (NYSE:HAE) – Investment analysts at Zacks Research reduced their FY2027 earnings estimates for Haemonetics in a research report issued to clients and investors on Monday, February 3rd. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $5.90 per share for the year, down from their prior estimate of $5.91. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

HAE has been the subject of a number of other reports. JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research report on Friday, December 6th. They set an “overweight” rating and a $116.00 price target on the stock. Raymond James raised Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price on the stock in a report on Friday, November 8th. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research note on Wednesday, December 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a research note on Tuesday, December 3rd. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $69.03 on Wednesday. The firm’s 50 day moving average is $78.16 and its two-hundred day moving average is $78.93. The firm has a market capitalization of $3.47 billion, a P/E ratio of 28.64, a PEG ratio of 1.07 and a beta of 0.39. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. Haemonetics has a 52 week low of $65.73 and a 52 week high of $97.97.

Haemonetics (NYSE:HAE) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. The company had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the business posted $0.99 earnings per share.

Institutional Investors Weigh In On Haemonetics

Several hedge funds have recently made changes to their positions in HAE. Wellington Management Group LLP raised its position in Haemonetics by 9.5% during the third quarter. Wellington Management Group LLP now owns 4,201,565 shares of the medical instruments supplier’s stock valued at $337,722,000 after buying an additional 363,702 shares during the period. Royce & Associates LP increased its holdings in shares of Haemonetics by 2.6% in the 3rd quarter. Royce & Associates LP now owns 1,210,546 shares of the medical instruments supplier’s stock valued at $97,304,000 after purchasing an additional 30,868 shares during the period. Geode Capital Management LLC increased its holdings in shares of Haemonetics by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier’s stock valued at $95,986,000 after purchasing an additional 21,547 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of Haemonetics by 29.5% during the third quarter. Thrivent Financial for Lutherans now owns 1,100,183 shares of the medical instruments supplier’s stock worth $88,433,000 after purchasing an additional 250,833 shares during the period. Finally, Boston Trust Walden Corp grew its position in Haemonetics by 13.1% during the fourth quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock valued at $71,500,000 after purchasing an additional 106,114 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.